To enhance the oral bioavailability of the antioxidants trans-resveratrol and trans-ε-viniferin from Vineatrol30 grapevine-shoot extract, the native powder was incorporated into micelles. A single dose, single blind, two arms crossover trial was conducted. Plasma and urine samples were collected at intervals up to 24 h after oral intake of native or micellar Vineatrol30 (500 mg), and resveratrol content was quantified and compared between formulations. Tolerability of the dose was also controlled by safety parameters in plasma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
12
University of Hohenheim
Stuttgart, Baden-Wurttemberg, Germany
Mean area under the curve (AUC) of plasma concentration vs. time of total trans-resveratrol [nmol/L*h]
Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Mean area under the curve (AUC) of plasma concentration vs. time of total trans-epsilon-viniferin [nmol/L*h]
Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Mean maximum plasma concentration (Cmax) of total trans-resveratrol [nmol/L]
Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Mean maximum plasma concentration (Cmax) of total trans-epsilon-viniferin [nmol/L]
Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Time to reach maximum plasma concentration (Tmax) of total trans-resveratrol [h]
Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Time to reach maximum plasma concentration (Tmax) of total trans-epsilon-viniferin [h]
Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Cumulative urinary excretion of total trans-resveratrol [nmol/g creatinine]
Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Cumulative urinary excretion of total trans-epsilon-viniferin [nmol/g creatinine]
Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase
Time frame: 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose
Serum aspartate transaminase activity [U/L]
Time frame: 0, 4, 24h post-dose
Serum alanine transaminase activity [U/L]
Time frame: 0, 4, 24h post-dose
Serum gamma-glutamyl transferase activity [U/L]
Time frame: 0, 4, 24h post-dose
Serum alkaline phosphatase activity [U/L]
Time frame: 0, 4, 24h post-dose
Serum bilirubin
Time frame: 0, 4, 24h post-dose
Serum uric acid [mg/dL]
Time frame: 0, 4, 24h post-dose
Serum creatinine [mg/dL]
Time frame: 0, 4, 24h post-dose
Serum total cholesterol [mg/dL]
Time frame: 0, 4, 24h post-dose
Serum HDL cholesterol [mg/dL]
Time frame: 0, 4, 24h post-dose
Serum LDL cholesterol [mg/dL]
Time frame: 0, 4, 24h post-dose
Serum triacylglycerols [mg/dL]
Time frame: 0, 4, 24h post-dose
LDL/HDL cholesterol ratio
Time frame: 0, 4, 24h post-dose
Serum cystatin C [mg/mL]
Time frame: 0, 4, 24h post-dose
Glomerular filtration rate [mL/min]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 0, 4, 24h post-dose
Serum glucose [mg/dL]
Time frame: 0, 24h post-dose